Citigroup Inc Revance Therapeutics, Inc. Put Options Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Aug 10, 2023	SELL	$24.7 - $37.61 $617,500 - $940,250	-25,000 Reduced 47.17%	28,000 $708,000
Q1 2023 May 11, 2023	SELL	$18.36 - $35.27 $10.4 Million - $19.9 Million	-565,000 Reduced 91.42%	53,000 $1.71 Million
Q4 2022 Feb 09, 2023	BUY	$18.32 - $30.66 $597,232 - $999,516	32,600 Added 5.57%	618,000 $11.4 Million
Q3 2022 Nov 10, 2022	BUY	$14.33 - $28.47 $8.39 Million - $16.7 Million	585,400 New	585,400 $15.8 Million
Q4 2021 Feb 10, 2022	BUY	$12.46 - $27.87 $1.47 Million - $3.29 Million	117,900 New	117,900 $1.92 Million

232

82.1M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.